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Abstract 
Background: In surgical patients with known malignancy, the odds ratio for an episode 
of a venous thromboembolism is approximately 6.5 compared to a group of patients 
without malignancy undergoing the same procedure [Heit et al.: Arch Intern Med 
2000;160:809–815].  
Case Report: We present a case of a 46-year-old Caucasian male with a history of 
adenocarcinoma of the rectum. The patient received neoadjuvant treatment prior to low 
anterior resection with diverting colostomy. He received short-term prophylaxis for 
venous thrombosis, but unfortunately developed a blood clot in a lower extremity 
several weeks after surgery.  
Conclusion: There is a well-defined role in carefully selected patients for the use of 
extended prophylaxis to prevent venous thromboembolic complications following 
cancer surgery. 
 
Introduction 
Venous thromboembolic disease is the leading cause of death in patients with cancer 
[2]. Patients undergoing surgery, who have known malignancy, are documented to have a 
higher risk of developing perioperative venous thromboembolic disease. The ESSENTIAL 
trial demonstrated that 75% of patients undergoing major cancer surgery did not receive 
appropriate extended venous thromboembolism prophylaxis [3]. The RISTOS project  
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demonstrated that a remarkable proportion of venous thromboembolic events occurred 
late (40% >21 days after surgery). 
We report the case of a patient diagnosed with adenocarcinoma who underwent a low 
anterior abdominal resection with diverting colostomy. This paper discusses the 
appropriate selection of patients who would benefit from extended venous 
thromboembolism prophylaxis. 
Case Presentation 
Our patient is a 45-year-old Caucasian male with a past medical history significant for asthma. He 
did not have any prior history of venous thromboembolic disease. He initially presented to his physician 
with a chief complaint of several weeks of abdominal bloating and diarrhea associated with tenesmus. 
The patient denied having had fever, weight loss, fatigue, or hematochezia. His diagnostic evaluation 
included a colonoscopy, which revealed the presence of a 5-cm ulcerated rectal mass. The biopsy was 
significant for adenocarcinoma of the rectum. Staging studies showed no evidence of metastatic disease. 
The patient was referred to medical oncology. He was treated with neoadjuvant 5-FU with oxaliplatin, 
in addition to concurrent external beam radiation to the rectum (4,500 cGy to the pelvic and inguinal 
lymph nodes and the rectal mass, with an additional 540 cGy to the rectal mass) over a period of 5 
weeks. Follow-up CT revealed no abdominal or pelvic lymphadenopathy. There was normal appearance 
of the rectum and distal sigmoid colon. There was no visualization of asymmetric wall thickening or 
soft-tissue mass. No perirectal lymphadenopathy was identified. The patient was referred to surgery, 
and the surgeon performed a low anterior resection with diverting ileostomy, mobilization of the splenic 
flexure, and proctoscopy. The duration of the surgery was approximately 3 h. The surgical staging of the 
rectal cancer was T3N1M0. 
Post-surgical pharmacologic venous thromboembolism prophylaxis was initiated the day after 
surgery. Pharmacologic prophylaxis was continued for the duration of the hospitalization (8 days). The 
patient did not receive extended pharmacologic venous thromboembolism prophylaxis after discharge 
from the hospital. 
Twenty-five days after surgery, the patient presented to his primary care physician with a chief 
complaint of left lower-extremity swelling. The clinician ordered a venous ultrasound, which revealed 
extensive deep vein thrombosis of the left saphenous and popliteal veins. 
Discussion 
Venous thromboembolic disease is a major contributor to morbidity and mortality in 
patients requiring cancer surgery. Identification of patients who would benefit from 
extended venous thromboembolism prophylaxis in the post-surgical setting is critical. 
The RISTOS project identified 5 risk factors for the development of venous 
thromboembolic disease for patients undergoing cancer surgery: (1) age >60 years; (2) 
previous venous thromboembolism; (3) advanced cancer; (4) anesthesia lasting >2 h, and 
(5) bed rest >2 days [4]. 
Several studies have demonstrated a statistically significant benefit of extended (28 
days) pharmacologic venous thromboembolism prophylaxis. ENOXACAN II evaluated 
patients undergoing abdominal or pelvic surgery for malignancy. Enoxaparin (40 mg s.q. 
daily) was provided for 6–10 days after surgery. Patients were then randomized to receive 
enoxaparin 40 mg s.q. daily for an additional 21 days or were given placebo. At day 31 
after surgery, venous ultrasound was performed. The placebo group exhibited a rate of 
thromboembolic disease of 12%, with a risk of hemorrhage of 3.6%. The group of patients 
receiving extended venous thromboembolism prophylaxis was found to have a rate of  
Case Rep Oncol 2011;4:115–117 
DOI: 10.1159/000324584 
Published online: 
February 25, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
117
thromboembolic disease of 4.8%, with an associated risk of hemorrhage of 5.1% (p = 0.02) 
[5]. 
CANBESURE was a randomized double-blinded study that evaluated patients 
undergoing abdominal or pelvic surgery for cancer. A dose of 3,500 IU s.q. of bemiparin 
was provided daily for 8 days after surgery. Patients were then randomized to receive 
placebo or bemiparin for an additional 20 days. Bilateral venography was performed after 
20 days. The rate of deep vein thrombosis in the placebo group was 4.6%. The group of 
patients who received extended venous thromboembolism prophylaxis had a rate of 0.8% 
(p = 0.01). Bleeding risk was not statistically different between placebo and extended 
prophylaxis groups [6]. 
Rasmussen et al. [7] evaluated patients undergoing major abdominal surgery, 
including patients with and without malignant disease. Post-surgical venous 
thromboembolism prophylaxis with dalteparin was given for 7 versus 28 days 
postoperatively. All patients underwent venography on day 28 after surgery. Venous 
thromboembolic disease rate was 16.3% for patients receiving 7 days of prophylaxis 
versus 7.3% for patients receiving 28 days of extended prophylaxis (p = 0.012) [7]. 
In conclusion, these studies indicate the need for the development of a process to 
screen patients undergoing cancer surgery for an increased risk of post-surgical venous 
thromboembolic disease. In patients identified as being at high risk, extended venous 
thromboembolism prophylaxis should be instituted preferably with a low-molecular-
weight heparin for a total duration of at least 28 days after surgery. 
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